This initiative from the Blood and Marrow Transplant Clinical Trials Network is for advancing hematopoietic cell transplantation (HCT) for all patients, particularly those with rare and challenging non-malignant blood diseases and hematological malignancies. The grant aims to support a robust clinical trials network to evaluate novel cell therapy (CT) and HCT approaches. Funds will establish a Data Coordinating Center (DCC) and core clinical sites, alongside supporting a limited number of trials directly. Additional studies will be fostered through collaborations with RO1 grantees, industry, and foundations. Recognizing the extended duration of HCT and CT trials—often beyond five years due to rare patient accrual, complex manufacturing, and long-term endpoints—a seven-year program is necessary to achieve these critical research objectives.
Opportunity ID: 348828
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-HL-24-011 |
| Funding Opportunity Title: | The Blood and Marrow Transplant Clinical Trials Network – Data Coordinating Center (U24 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 21, 2023 |
| Last Updated Date: | Jun 21, 2023 |
| Original Closing Date for Applications: | Oct 02, 2023 |
| Current Closing Date for Applications: | Oct 02, 2023 |
| Archive Date: | Nov 07, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Private institutions of higher education Special district governments Independent school districts State governments Public and State controlled institutions of higher education City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public housing authorities/Indian housing authorities Small businesses County governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this initiative is to advance hematopoietic cell transplantation (HCT) for all patients, but particularly for patients with rare and difficult to treat non-malignant blood diseases and hematological malignancies. This will be accomplished by supporting a clinical trials network to evaluate novel cell therapy (CT) and HCT approaches. A Data Coordinating Center (DCC) and core clinical sites will be supported by funds requested as part of this initiative, as well as a limited number of trials. Additional studies and trials will be funded through collaborations with RO I-funded grantees, industry, and foundations. Multiple factors extend the duration of most HCT and CT trials beyond 5 years, including rare patient populations (and hence accrual periods of up to 5 years), complex cell manufacturing processes, and composite endpoints such as disease-free survival and chronic graft versus-host disease free survival that occur 2 or more years post-transplant. A seven year program to support these activities is needed. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-24-011.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 348828 Full Announcement-RFA-HL-24-011 -> RFA-HL-24-011-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00282244 | Sep 02, 2023 | Oct 02, 2023 | View |
Package 1
Mandatory forms
348828 RR_SF424_5_0-5.0.pdf
348828 PHS398_CoverPageSupplement_5_0-5.0.pdf
348828 RR_OtherProjectInfo_1_4-1.4.pdf
348828 PerformanceSite_4_0-4.0.pdf
348828 RR_KeyPersonExpanded_4_0-4.0.pdf
348828 RR_Budget10_3_0-3.0.pdf
348828 PHS398_ResearchPlan_5_0-5.0.pdf
348828 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
348828 RR_SubawardBudget10_30_3_0-3.0.pdf
348828 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
